Ghisallo Capital Management LLC Makes New $8.25 Million Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Ghisallo Capital Management LLC acquired a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 1,100,000 shares of the company's stock, valued at approximately $8,250,000. Ghisallo Capital Management LLC owned 0.39% of Recursion Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of RXRX. ARK Investment Management LLC lifted its position in shares of Recursion Pharmaceuticals by 14.5% in the second quarter. ARK Investment Management LLC now owns 28,142,918 shares of the company's stock valued at $211,072,000 after acquiring an additional 3,555,357 shares in the last quarter. Baillie Gifford & Co. raised its position in shares of Recursion Pharmaceuticals by 10.5% in the second quarter. Baillie Gifford & Co. now owns 26,589,936 shares of the company's stock valued at $199,425,000 after buying an additional 2,522,132 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Recursion Pharmaceuticals by 2.2% during the first quarter. Vanguard Group Inc. now owns 16,014,764 shares of the company's stock valued at $159,667,000 after buying an additional 349,554 shares during the period. Mubadala Investment Co PJSC acquired a new stake in Recursion Pharmaceuticals during the fourth quarter worth approximately $128,041,000. Finally, Kinnevik AB publ grew its stake in Recursion Pharmaceuticals by 14.4% in the 2nd quarter. Kinnevik AB publ now owns 11,905,668 shares of the company's stock worth $89,293,000 after acquiring an additional 1,500,000 shares during the period. Hedge funds and other institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Stock Up 3.1 %

RXRX stock traded up $0.19 during mid-day trading on Wednesday, hitting $6.36. 1,614,335 shares of the company were exchanged, compared to its average volume of 5,853,970. The firm has a fifty day simple moving average of $6.95 and a 200 day simple moving average of $8.12. The company has a market capitalization of $1.79 billion, a PE ratio of -3.99 and a beta of 0.82. Recursion Pharmaceuticals, Inc. has a twelve month low of $4.97 and a twelve month high of $15.74. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The business had revenue of $14.42 million for the quarter, compared to the consensus estimate of $11.96 million. During the same quarter in the previous year, the firm earned ($0.38) EPS. The firm's revenue for the quarter was up 30.9% on a year-over-year basis. On average, research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently weighed in on RXRX shares. Needham & Company LLC cut their target price on Recursion Pharmaceuticals from $16.00 to $11.00 and set a "buy" rating on the stock in a research report on Wednesday, September 4th. KeyCorp decreased their target price on Recursion Pharmaceuticals from $16.00 to $12.00 and set an "overweight" rating for the company in a report on Thursday, July 11th. Jefferies Financial Group dropped their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating for the company in a research report on Tuesday, September 3rd. Finally, Leerink Partners dropped their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating on the stock in a research note on Tuesday, September 3rd. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $9.40.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 50,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $7.48, for a total value of $374,000.00. Following the completion of the transaction, the chief executive officer now directly owns 758,738 shares in the company, valued at $5,675,360.24. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 50,000 shares of the firm's stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $7.48, for a total value of $374,000.00. Following the sale, the chief executive officer now directly owns 758,738 shares in the company, valued at $5,675,360.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Michael Secora sold 15,000 shares of the company's stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $7.32, for a total transaction of $109,800.00. Following the transaction, the chief financial officer now owns 1,292,218 shares of the company's stock, valued at approximately $9,459,035.76. The disclosure for this sale can be found here. Insiders have sold a total of 231,682 shares of company stock worth $1,632,044 over the last quarter. 15.75% of the stock is owned by company insiders.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.